Proimmune expands into new 18,000 sq ft global headquarters enabling major expansion in immunology and life science innovation ProImmune Ltd, a global leader in life science reagents and services, today announced the opening of its new global headquarters building at Oasis Park, Oxford, enabling significant expansion of its operations and capacity to serve its global client base.
https://www.news-medical.net/n....ews/20251022/Proimmu

Study shows mRNA-based COVID vaccines enhance effectiveness of immune checkpoint therapy Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning treatment, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center.
https://www.news-medical.net/n....ews/20251022/Study-s

Oral targeted therapy shrinks tumors in over 70% of patients with HER2-mutant NSCLC The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University of Texas MD Anderson Cancer Center.
https://www.news-medical.net/n....ews/20251022/Oral-ta

VT3989 shows promising antitumor activity in refractory mesothelioma patients The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led by researchers from The University of Texas MD Anderson Cancer Center.
https://www.news-medical.net/n....ews/20251022/VT3989-

The future of automation: Machine learning–driven hepatocyte and organoid counting DeNovix discusses how customer demand inspired the development of specialized CellDrop applications for hepatocytes and organoids.
https://www.news-medical.net/n....ews/20251022/The-fut